Applied Optoelectronics, Inc. filed a Form 8-K on November 4, 2026, disclosing that it entered into a new credit agreement with East West Bank on October 30, 2026, replacing a prior facility and creating a direct financial obligation.
Rallybio Corporation filed a Form 8-K on November 4, 2026, disclosing stockholder approval of the Avenzo Therapeutics 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the company's annual meeting, both contingent on completion of a pending merger with Avenzo.
LiveOne, Inc. filed a current report on Form 8-K on November 4, 2026, disclosing that on October 29, 2026, the company and certain subsidiaries entered into a Forbearance Agreement and Amendment to Debentures with holders of its 11.75% Original Issue Discount Senior Secured Convertible …
PodcastOne, Inc. filed a Form 8-K on November 4, 2026, disclosing that on October 29, 2026, it entered into a Forbearance Agreement and Amendment to Debentures with holders of LiveOne's 11.75% Original Issue Discount Senior Secured Convertible Debentures.
Fly-E Group, Inc. filed a Form 8-K on November 4, 2026, disclosing that Peapack Private Bank & Trust submitted a complaint to the Supreme Court of the State of New York, County of Queens, on October 30, 2026, seeking at least $3.9 million in …
CF Industries Holdings, Inc. filed a Form 8-K with the SEC on November 4, 2026, disclosing a conference call and accompanying presentation related to its results for the quarter ended September 30, 2026.
NetSol Technologies, Inc. filed a Form 8-K on November 4, 2026, disclosing that its Pakistani subsidiary, NetSol Technologies, Ltd., published quarterly results of operations and financial condition for the period ended September 30, 2026, on the Pakistan Stock Exchange.
Finward Bancorp filed a Form 8-K on November 4, 2026, disclosing that its Board of Directors declared a quarterly common stock dividend of $0.12 per share, payable December 2, 2026, to shareholders of record as of November 18, 2026.
Evommune, Inc. filed a current report on November 4, 2026, disclosing an exclusive license agreement with Hinova Pharmaceuticals Inc. for VAV1 degrader EVO570 and a concurrent $30.0 million private placement of common stock.
NOVAGOLD Resources Inc. filed a Form 8-K on November 4, 2026, disclosing the results of a special meeting held November 3, 2026, at which shareholders voted to approve an arrangement under which New NOVAGOLD Corporation will acquire all outstanding NOVAGOLD common shares and consolidate …